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A
 
BSTRACT
 
Cyclic nucleotides are powerful signaling molecules
and their sole means of removal is through the action
of cyclic nucleotide phosphodiesterases (PDEs). Elevat-
ing levels of cAMP is beneficial in many diseases,
including neurological conditions, cancers, viral infec-
tions and most inflammatory disorders. There are 11
known PDE families, with PDE4 being the most highly
expressed. Evidence of the clinical usefulness of PDE4
inhibition has come from the use of specific chemical
inhibitors and the generation of knock-out mice
models. There exists an extensive range of PDE4 family
members, because there are four subfamilies, each
encoded by their own gene and each capable of
generating multiple isoforms. Several members of the
PDE4 family are found to be expressed in every cell
and tissue studied and evidence is now being uncovered
indicating unique functions for each. Their actions are
controlled by their expression patterns, subcellular
location and interaction with other signaling pathways.
The first generation of PDE4 inhibitors, although
potent anti-inflammatory agents, failed as pharma-
ceuticals owing to their emetic and gastric side-effects.
A new generation of chemical inhibitors is now
nearing the market, which display greatly reduced
side-effects. In the future lies the generation of more
specific inhibitors that will focus upon particular
diseases. This will be achieved by targeting specific
PDE4 family members. Because the current target of
chemical inhibition (the catalytic site) is virtually identi-
cal between isoforms, this specificity is likely to be
achieved by blocking the enzyme’s interaction with
other signaling cascades.
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I
 
NTRODUCTION
 
The potent anti-inflammatory effects of elevating cellular
cAMP levels have been known for many years.
 
1
 
 More
recently, our understanding of the mechanisms control-
ling the concentration of this second messenger has
allowed the identification of new targets for therapeutic
intervention. As important regulators of cellular function,
the synthesis and degradation of cAMP is tightly regu-
lated, with the sole means of removing cAMP through
the action of cyclic nucleotide phosphodiesterases
(PDEs). The PDE4 family is the predominant cAMP-
hydrolysing enzyme in cells of the immune system,
making them a good target for drug therapy.
 
2
 
The activation and recruitment of inflammatory cells
and the unregulated release of excessive levels of
cytokines is implicated in many allergic and autoimmune
diseases, such as rheumatoid arthritis, irritable bowel
disease, atopic dermatitis and psoriasis. Recruitment of
immune cells and release of proinflammatory mediators
are all blocked by the action of PDE4 inhibitors. The
PDE4 inhibitors can also cause airway smooth muscle
relaxation. Although they are not as potent as 
 
β
 
-adrenergic
agonists in relaxation, this dual role suggests great
potential in the treatment of airway disease. Advanced
clinical trials have proved PDE4 inhibitors to have benefit
in chronic obstructive pulmonary disease (COPD),
asthma, allergic rhinitis and rheumatoid arthritis.
 
3,4
 
Many PDE4 inhibitors have shown a high frequency of
observed side-effects, such as excessive gastric acid
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secretion, nausea and vomiting.
 
2,5
 
 Therefore, the current
challenge is to improve the separation between these
side-effects and the efficacy of the drug. The presence of
multiple isoforms in association with differential expres-
sion patterns and regulation among target tissues, pro-
vides many opportunities to develop a new generation of
specific inhibitors lacking undesirable side-effects.
The PDE4 family consists of four subfamilies, each
coded by its own gene and each capable of generating
multiple splice variants.
 
6
 
 All members possess a common
catalytic region conferring similar kinetic properties and
ion requirements upon the isoforms. The N-terminal and
C-terminal regions show variability, containing motifs
involved in the regulation of catalytic activity and intra-
cellular targeting of the enzyme. The value of targeting
subfamilies is demonstrated using knock-out mice defi-
cient in one of the PDE4 genes. Animals lacking the
 
PDE4B
 
 gene have an impaired immune system,
 
7
 
 whereas
those lacking the 
 
PDE4D
 
 gene showed effects in their
airways.
 
8
 
 More focused inhibitors may also possess better
efficacy because it maybe possible to select against inhib-
iting the PDE4 causing the side-effects.
The cellular mechanisms controlling the location and
activity of the PDE4 family are extremely complex. Much
work has gone into identifying regions within the PDE
enzyme responsible for this tight control.
 
6
 
 These control-
ling mechanisms and their unique sites on the enzyme
represent future target areas that could allow targeted
disruption of the cAMP signaling system in specific
regions.
 
P
 
HOSPHODIESTERASES
 
The PDE family is a large family of catalytically active
enzymes.
 
9
 
 There are currently 11 gene families identi-
fied,
 
9,10
 
 differing in their substrate specificity and K
 
m
 
,
most encoded on multiple genes and with many able to
generate multiple splice variants. Although the catalytic
region is conserved throughout the families, the catalytic
regions are sufficiently different to allow the generation
of family specific inhibitors. All PDE enzymes possess
sequence differences around their N- and C-terminal
regions. These unique regions play important roles in
controlling the function and location of these enzymes.
All PDE4 isoforms have the same general structure.
 
10
 
Four genes, labeled A–D, encode this family, with each
gene capable of generating a range of isoforms differing
at their N-terminal regions. The catalytic region occupies
the central portion of the enzyme and is conserved within
members of the same gene family (Fig. 1a). Regions
N-terminal to the catalytic region show variability and
contain motifs involved in the regulation of catalytic
activity and intracellular targeting. Within this variable
N-terminal region in the PDE4 family are found two
sections of conservation termed the Upstream Conserved
Regions (UCR). The C-terminus of UCR1 interacts with
the N-terminus of UCR2 and this UCR1/2 domain is also
suggested to then interact with the catalytic domain
through UCR2.
 
11
 
 These UCR regions play crucial roles in
regulating the enzymatic activity of PDE4.
 
I
 
NHIBITORS
 
 
 
OF
 
 PDE4 
 
ENZYMES
 
Inhibitors of PDEs have been used as anti-inflammatory
agents for many years. Compounds such as caffeine
and theophylline possess weak PDE inhibitory abilities
and have been used to treat asthma and COPD.
 
2,5
 
Recently, interest has developed in the PDE4 family of
cAMP-specific PDEs as anti-inflammatory agents. Mul-
tiple members of all four PDE4 subfamilies have been
identified in almost all cell types studied and are highly
expressed in cells of the immune system.
 
2,5
 
A great many inhibitors of PDE4 have demonstrated
potent anti-inflammatory effects in a wide range of
cell-based assay systems, many using human-derived
material. Inhibition of PDE4 blocks the release of cyto-
kines and prevents immune cell infiltration. A few of these
compounds have advanced to clinical trials, extending
the observation to human inflammatory conditions.
 
2,3
 
More recently, advanced clinical trials have proved PDE4
inhibitors to have distinct benefits in asthma and
COPD.
 
2,3
 
 Through cAMP elevation, not only do PDE4
inhibitors reduce the inflammatory response, but they can
also relax airway smooth muscle. Therefore, they are
of particular interest in the development of agents for
chronic airway diseases, such as asthma and COPD,
because they have the added advantage of being able to
target the underlying inflammatory condition that causes
the lung damage.
 
12
 
The first generation of specific PDE4 inhibitors, such
as rolipram and RO-20 1724, showed great promise as
anti-inflammatory agents, being capable of potently
blocking many immune cell functions.
 
2,5
 
 However, their
utility was greatly degraded by the observation of equally
potent side-effects. These side-effects of emesis, nausea
and increased gastric acid secretion eventually resulted in
the failure of these compounds.
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S
 
ECOND
 
-
 
GENERATION
 
 PDE4 
 
INHIBITORS
 
Using the information gained on the side-effects
observed with the original PDE4 specific inhibitors, many
companies undertook the development of a second
generation of compounds with greatly reduced side-
effects. The observed gastrointestinal discomfort is prob-
ably due to increased acid secretion from parietal cells.
Emesis, the other major observed side-effect, is believed
to be due to binding of the inhibitor to a high-affinity site
in the brain. It is not yet known whether there is a
common mechanism to these side-effects.
Pharmaceutical companies have used a high-affinity
binding-site assay to select for compounds that preferen-
tially bind to a low-affinity binding site and, thus, reduce
the emetic effect.
 
13,14
 
 Compounds selecting against this
high-affinity site derived from rat brain are now being
developed.
 
15
 
 The cause of these side-effects remains
poorly understood. A 
 
PDE4D
 
-deficient mouse anesthesia
model has been used to suggest that a member of this
subfamily is responsible for the emetic side-effects.
 
16
 
However, compounds more selective for the PDE4D sub-
family do not exhibit enhanced side-effects.
Mice deficient in PDE4D demonstrate further impor-
tant roles for this subfamily in showing a greatly reduced
ability for muscarinic cholinergic agonists, such as acetyl-
choline, to cause bronchoconstriction.
 
17
 
 The mice retain
a functioning contraction mechanism because their
airways can contract through alternative stimulants. It is
thought that this effect is caused by a loss in the ability
of the muscarinic receptor to decrease cAMP levels,
presumably through the action of a PDE4D.
 
Fig. 1
 
(a)
 
 
 
All phosphodiesterase (PDE) 4 isoforms have the same general structure.
 
10
 
 The catalytic region occupies the central
portion of the enzyme and is conserved within members of the same gene family. Regions N-terminal to the catalytic region show
variability and contain regulatory motifs. Within this variable N-terminal region in the PDE4 family are found two sections of conser-
vation termed the Upstream Conserved Regions (UCR). These UCR regions play crucial roles in regulating the enzymatic activity of
PDE4. (b)
 
 
 
An increasing number of protein–protein interactions involving PDE4 enzymes have been identified. These interactions
hold the PDE within a discrete location within the cell causing the cAMP concentration to be tightly regulated.
 
19
 
 Disrupting these
binding interactions would specifically remove the PDE from these compartments, causing local cAMP concentrations to rise, result-
ing in controlled and potent effects upon a specific signaling pathway. Chemical disruption of these interactions could be used to
target specific inflammatory processes, leading to potent and selective anti-inflammatory agents. This figure highlights some of the
regions identified in the regulatory control of a long-form PDE4D. AKAP, A-kinase anchoring protein; mAKAP, muscle-selective
AKAP; PKA, protein kinase A; KIM, kinase interaction domain; ERK, extracellular signal-regulated kinase.
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Phosphodiesterase 4D is the major PDE4 subfamily
expressed in immune cells; however, a mouse deficient in
this gene shows little compromise in its lipopolysaccha-
ride (LPS)-stimulated tumor necrosis factor (TNF)-
 
α
 
 levels.
In contrast, 
 
PDE4B
 
-knock-out mice show an impaired
immune response.
 
7
 
 This demonstrates that even though
all PDE4 subfamilies are expressed in immune cells, there
is specificity in their function. There appears little redun-
dancy in their function and, thus, inhibition of specific
subfamilies, or even isoforms, could have as potent anti-
inflammatory effects as global inhibition of the entire
PDE4 family.
Others have developed inhibitors more selective
for specific PDE4 subfamilies. Although the catalytic
regions within the PDE4 subfamilies possess very similar
sequences, there are some subtle differences. It is now
known that the unique N-terminal regions interact with
the catalytic site, increasing the differences between sub-
families that can be used in the development of selective
inhibitors.
 
6
 
The development of PDE4D-selective compounds
suggests that the catalytic region can exhibit usable dif-
ferences. These PDE4D-selective inhibitors have shown
good efficacy in cell-based anti-inflammatory models.
Therefore, there has been some success in the develop-
ment of subfamily selective inhibitors; however, it would
be predicted that the potential for more selectivity is
limited if the inhibitor compounds are targeted against
the catalytic site of the enzyme. The development of PDE4
inhibitors targeted to the catalytic site has been reviewed
extensively by Burnouf and Pruniaux.
 
12
 
T
 
ARGETING
 
 
 
NON
 
-
 
CATALYTIC
 
 
 
SITES
 
So far, all inhibitors of the PDE4 family have been
targeted against the catalytic site of the enzyme.
Although this guarantees inhibition of the enzyme, it
makes it very hard to be selective for particular PDE4
isoforms involved in controlling specific inflammatory
processes.
 
18
 
 It may not be necessary to inhibit the
activity of PDE4 enzymes through catalytic site inhibi-
tors to provide an anti-inflammatory outcome. Instead,
by disrupting the specific mechanisms used to control
this large family of enzymes, compounds could be
developed that would only block defined signaling
processes.
The function and location of PDE4 enzymes are highly
regulated and this is possibly the reason why so many
isoforms are expressed in cells. Through interactions with
signaling pathways, certain PDE4 isoforms can play
specific roles in controlling the local concentration of
cAMP in defined areas within the cell. This tight regula-
tion of cAMP allows for the differential regulation of sig-
naling cascades depending upon how they are activated
and where they lie within the cell.
Current research has started to identify the role of spe-
cific PDE4 isoforms in a multitude of signaling cascades.
Sequence analysis of PDE4 isoforms identifies many
potential phosphorylation sites, some of whose action
has now been detailed.
 
20,23,25
 
 Phosphorylation at these
sites leads to a rapid change in activity of the enzyme.
Physical interactions of PDE4 enzymes with key com-
ponents of cellular signaling pathways have also been
identified. The specific binding of PDE4 isoforms to
members of other signaling cascades allows these
enzymes to exert controlling influences on many path-
ways involved in inflammatory processes.
 
6
 
An increasing number of protein–protein interactions
involving PDE4 enzymes have been identified.
 
26,32,38,41,43
 
Most of these involve a single PDE4 isoform, the specifi-
city of binding being controlled by sequences within the
N-terminal region of the protein (Fig. 1b). It is believed
that these interactions hold the PDE within a discrete
location within the cell, causing the cAMP concentration
to be tightly regulated.
 
19
 
 Disrupting these binding inter-
actions would specifically remove the PDE from these
compartments, causing local cAMP concentrations to
rise, resulting in controlled and potent effects upon a
specific signaling pathway. Chemical disruption of
these interactions could be used to target specific
inflammatory processes, leading to potent and selective
anti-inflammatory agents. Alternatively, disruption of
the phosphorylation-mediated control of these enzymes
would result in the local deregulation of cAMP, with
resultant anti-inflammatory action. As an added advan-
tage of this approach, blocking these mechanisms would
have little effect upon the catalytic activity of the enzyme
so, where the targeted isoform was associated with alter-
native pathways, there would be no disruption. This
approach has been proved to be a viable option through
the following examples.
 
Phosphorylation as a means of control
 
Phosphodiesterase 4 isoforms possess many putative
phosphorylation sites, providing the potential of many
possible kinase-driven controlling mechanisms. A number
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of these sites have been demonstrated to be true
phosphorylation sites for specific kinases.
 
20,23,25
 
It is perhaps not surprising that protein kinase A (PKA),
the protein kinase activated by cAMP, plays an important
functional role for the PDE4 family. A PKA phosphory-
lation consensus sequence has been identified within
the  N-terminal UCR1 region of all long-form PDE4
enzymes
 
20
 
 (Fig. 1b). Phosphorylation at this site causes
marked activation of the enzyme, demonstrating a classic
negative feedback mechanism. As cAMP levels increase,
PKA is activated, leading to the increase in activity of the
cAMP PDE, returning the levels of cAMP to basal and
lowering PKA activity.
 
21,22
 
The discovery of a site for extracellular signal-
regulated kinase (ERK) mitogen-activated protein kinase
(MAPK) phosphorylation within the catalytic domain of all
PDE4 enzymes added a layer of complexity to the simple
PKA controlling mechanism.
 
23
 
 The effect of phosphory-
lation at this site is dependent upon how much of an
N-terminal controlling region the PDE possesses
 
24
 
(Fig. 2). Long-form enzymes, possessing both UCR1 and
UCR2, are rapidly inhibited by ERK phosphorylation,
leading to a local increase in cAMP and activation of
PKA. Protein kinase A then phosphorylates the PDE at the
UCR1 site, causing recovery of PDE activity. This results in
the lowering of cAMP back to basal concentrations and
the switching off of PKA. This whole process takes minutes
and gives the cell a means of a short, controlled increase
in PKA.
In contrast, ERK phosphorylation of short-form PDE4
isoforms, lacking UCR1, causes a sustained activation of
the enzyme and a lowering of the local cAMP concentra-
tion. In ultrashort PDE4 isoforms, lacking both UCR1 and
the N-terminal region of UCR2, ERK phosphorylation
results in a sustained inhibition of the enzyme.
 
24
 
 Thus,
phosphorylation at a single site can have dramatically
different outcomes depending upon which isoform is
being targeted.
Lipopolysaccharide stimulation of the immune system
results in the activation of a number of signaling
cascades. In the U937 monocytic cell line, the activa-
tion of PDE4A4 upon LPS treatment of cells was medi-
ated through a phosphatidylinositol 3-kinase-controlled
pathway.
 
25
 
 Although PDE4A4 makes up a small propor-
tion of the total cellular PDE4 activity in U937 cells, it
has a powerful controlling influence upon the phos-
phorylation of cAMP response element-binding protein
(CREB),
 
25
 
 suggesting a key role in inflammatory signal-
ing processes.
 
Protein–protein interactions as controlling 
mechanisms
 
In addition to regulation through protein kinases, the
location of PDE4 enzymes within the cell is also carefully
controlled through their interaction and regulation by
association with other proteins. The PDE4A5 isoform
provides a good example of this.
 
26
 
 Mutation experiments
where the N-terminus of this enzyme was progressively
truncated identified multiple regions controlling its intra-
cellular distribution. Two sites were found in the unique
N-terminal region, which mediated localization within
the cell margins. A third membrane association region
was identified in the N-terminal portion of the UCR2
region and this allowed PDE4A5 to localize in the
perinuclear region.
One of these unique N-terminal sites has been studied
extensively. This is a proline-rich region that was found to
specifically control the interaction of this PDE with the
SH3 domain of Src tyrosine kinases.
 
26
 
 Endogenous
PDE4A5 immunoprecipitated from rat brains was found
to be associated with Src tyrosine kinases, demonstrating
this interaction occurs in real cellular systems. The human
form of PDE4A5, PDE4A4, also forms complexes with Src
tyrosine kinases, although this enzyme has an additional
proline-rich region within the LR2 region.
 
27
 
 Binding Src to
this region was found to alter the sensitivity of the enzyme
to inhibition by rolipram,
 
27
 
 suggesting that this interaction
causes an alteration within the catalytic site.
Interestingly, although PDE4A4/A5 is the only member
of the PDE4A subfamily capable of existing in a complex
with Src tyrosine kinases, it is not the only PDE4 using this
controlling mechanism. Phosphodiesterase 4D4 also
contains an N-terminal proline-rich region and has been
shown to associate with Src kinases through their SH3
domains.
 
28
 
The large family of Src tyrosine kinases is known to be
involved in many cellular pathways, a number of which
are sensitive to PKA action and, thus, local cAMP concen-
trations. By holding a PDE4 in close proximity, the cAMP
concentration around the Src kinase can be carefully
controlled. The tyrosine kinase Csk (C-terminal Src
kinase) controls signaling through the T cell receptor.
 
29
 
 In
the resting state, Csk is located in a membrane domain,
from where it is released upon T cell receptor activation,
leading to tyrosine phosphorylation of the receptor.
Increased levels of cAMP reduce the levels of Csk dissoci-
ation from the membrane domains, reducing T cell sign-
aling. It could be envisaged that association of a PDE
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with Csk would control cAMP levels, allowing activation
of the receptor.
Src is itself regulated through phosphorylation and it
has been found that prostaglandin (PG) E
 
2
 
-activated
PKA inhibits this tyrosine kinase.
 
30
 
 This inhibitory effect
is dependent upon Csk being located in membrane
domains. A mechanism is proposed where Src is inhibited
through the action of Csk in a cAMP–PKA-mediated
manner, controlled by G-protein-coupled receptors.
Proof that the interaction with Src kinases plays a role
in the location of the PDE was shown using PDE4A5,
which contains a caspase-3 cleavage site within its
 
Fig. 2
 
The effect of phosphodiesterase (PDE) 4 phosphorylation by extracellular signal-regulated kinase (ERK) mitogen-activated
protein kinase is dependent upon how much of an N-terminal controlling region the PDE possesses.
 
24
 
 Long-form enzymes such as
PDE4D3, possessing both Upstream Conserved Regions (UCR) 1 and UCR2, are rapidly inhibited by ERK phosphorylation, leading
to a local increase in cAMP and activation of protein kinase A (PKA). Protein kinase A then phosphorylates the PDE at the UCR1 site,
causing recovery of PDE activity. This results in the lowering of cAMP back to basal concentrations and the switching off of PKA. This
whole process takes minutes and gives the cell a means of a short, controlled increase in PKA. In contrast, ERK phosphorylation of
short-form PDE4 isoforms such as PDE4D1, lacking UCR1, causes a sustained activation of the enzyme and a lowering of the local
cAMP concentration. In ultrashort PDE4 isoforms like PDE4D2, lacking both UCR1 and the N-terminal region of UCR2, ERK
phosphorylation results in a sustained inhibition of the enzyme. Thus, phosphorylation at a single site can have markedly different
outcomes depending upon which isoform is being targeted.
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N-terminus.
 
31
 
 Cleavage at this site results in the loss of
the N-terminal portion containing the proline-rich, SH3-
binding domain. Rat1 fibroblasts undergoing apoptosis
demonstrate this reaction, which results in a redistribution
of the enzyme away from the perinuclear region. This also
provides an insight into the action a compound disrupt-
ing this interaction would have on the target cell. By
blocking the binding to Src, the PDE4 would no longer
exist in association with the particular pathway, allowing
local cAMP concentrations to rise.
Just as PKA is involved in the control of PDE4 activity,
the components of its signaling pathway also control
PDE4 location. Protein kinase A is regulated through the
distribution of the enzyme to specific intracellular regions.
A-Kinase anchoring proteins (AKAPs) are the mechanism
by which the cellular location of PKA is controlled.
The AKAPs are a large family of proteins that bind to the
dimerization site of the RII regulatory subunit of PKA; they
also act as scaffold molecules for a number of signaling
molecules.
 
32
 
 The constitutively active catalytic PKA
subunit is held by the regulatory PKA subunit. Upon
increases in cAMP levels, the catalytic unit is released,
allowing it to phosphorylate its targets.
It is perhaps not surprising then that the PDE4 isoforms
are also found to associate with AKAPs, allowing PKA
activity to be tightly regulated. In sertoli cells, PDE4D3
is held with PKA–RII
 
α
 
 in an enzyme complex through
the association with AKAP450. Through a site within the
unique N-terminus of PDE4D3, muscle-selective AKAP
(mAKAP) is found to be associated.
 
32
 
 In AKAP450, a
separate site found within the UCR2 region of PDE4D3
mediates the interaction.
 
33
 
In human airway smooth muscle, increasing cAMP
concentrations either by stimulation of 
 
β
 
2
 
-adrenergic
receptors or through treatment with PDE4 inhibitors,
causes a reduction in the release of the eosinophil-
activating cytokines granulocyte–macrophage colony
stimulating factor (GM-CSF), RANTES and eotaxin by
TNF-
 
α
 
 or interleukin (IL)-1b.
 
34
 
 Interleukin-1b causes the
release of these cytokines through the action of MAPKs,
which have been shown to be regulated by PDE4-
controlled cAMP levels.
 
35
 
 Unlike steroids, cAMP elevation
by 
 
β
 
-adrenergic receptor agonists or PDE4 inhibitors
has been found to have no direct effect upon TNF-
 
α
 
-
mediated IL-8 release from airway smooth muscle.
However, cAMP elevation greatly enhances the steroid-
mediated inhibition of IL-8.
 
35
 
Stimulation of 
 
β
 
2
 
-adrenergic receptors using selective
 
β
 
2
 
-adrenergic receptor agonists causes a decrease in M2
muscarinic receptors in human embryonic lung cells.
 
36
 
This lowering of receptor number is mimicked by forskolin
and non-hydrolysable analogs of cAMP, demonstrating a
cAMP-dependent mechanism. Prolonged treatment with
 
β
 
2
 
-adrenergic receptor agonists causes both a reduction
in M2 receptor number at the cell surface and a reduc-
tion in muscarinic receptor mRNA, both believed to occur
through the action of PKA.
 
37
 
 Binding of muscarinic ago-
nists, such as acetylcholine, induces contraction of airway
smooth muscle. By reducing M2 receptor numbers,
 
β
 
2
 
-adrenergic receptor agonists decrease the contractile
ability of muscarinic agonists. Therefore, inhibition of
PDE4 and the resultant increase in PKA activity would
have a comparable pharmacologic effect of reducing
airway hyperresponsiveness, a similar outcome to that
seen in the PDE4D-deficient mouse.
 
β
 
-Adrenergic receptor agonists provide broncho-
protection in asthma through the previously described
mechanism.36 Signaling through this receptor leads to the
production of cAMP through activation of adenylate
cyclase by Gs. Phosphorylation of the receptor by PKA,
activated by the rise in cAMP, leads to a switch to signal-
ing through Gi, blocking cAMP production. β-Arrestin
acts as a scaffolding protein, playing a role in the desen-
sitization of G-protein-coupled receptors, such as the
β2-adrenergic receptors.38 Upon receptor binding and Gs
activation, the kinase G-protein-coupled receptor kinase
(GRK) is activated. This phosphorylates the receptor,
leading to the recruitment of β-arrestin, resulting in a
switching of signaling to Gi. β-Arrestin has been shown to
associate with PDE4D3 and PDE4D5 isoforms.39 In addi-
tion, it is believed that β-arrestin controls the desensitiza-
tion of the receptor through the recruitment of the PDE4,
reducing cAMP synthesis through G-protein switching
and enhancing its degradation through the presence of
the PDE.39 Stimulation of HEK293 cells overexpressing
the β2-adrenergic receptor results in PKA activation and
recruitment of β-arrestin and PDE4D isoforms to the
receptor.38
Two sites of interaction have been identified on PDE4,
one in the common catalytic region and one in the
unique N-terminal region, controlling specificity of bind-
ing.40 There are two corresponding sites of interaction on
β-arrestin, one in the extreme N-terminus and one in the
C-terminal region, allowing preferential interaction with
PDE4D5 over other PDE4 isoforms. Breaking this regula-
tion by either inhibition of PDE4 or transfection of cells
with a catalytically inactive PDE4 enzyme leads to the
more rapid desensitization of the β2-adrenergic receptor,
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with enhanced switching from Gs to Gi and a reduction in
M2 muscarinic receptor downregulation.
Not only does ERK phosphorylation cause isoform
specific alterations in activity, but these kinases also
physically bind PDE4 enzymes.41 This interaction occurs
through two distinct binding sites within the catalytic
region of PDE4, one termed the FQF region after its
amino acid sequence and the other, the KIM (kinase
interaction domain). The KIM sequence is a binding motif
common for all members of the MAPK family; however,
the presence of the additional FQF sequence confers
specificity of binding towards ERK.
Phosphodiesterase 4D5 has been found associated
with receptor for activated C kinase 1 (RACK1) in many
cell types.42 It is suggested that RACK1 acts as a scaffold-
ing protein, recruiting and holding PDE4D5 within a
specific region of the cell, thus controlling local cAMP
concentrations. RACK1 is also found to interact with Src,
integrin β-subunits and the common β-chain of the IL-3
and IL-5 receptors.43 It consequently forms a multienzyme
complex in which PDE4 is also present, allowing the
control of cAMP and PKA levels.
RACK1 binds PDE4D5 in a region within its unique
N-terminus called RAID143 (RACK1 interaction domain).
This is a helical domain consisting of hydrophobic amino
acids. The amino acids involved in the binding of RACK1
to PDE4D5 have been carefully mapped, allowing the
generation of a binding site model. This information
could be used in the generation of specific compounds
capable of disrupting this interaction.
CONCLUSIONS
Inhibitors of the PDE4 family have been shown to be
potent anti-inflammatory agents. Their clinical use has
been severely limited due to the potent side-effects
observed. The latest inhibitors emerging show greatly
reduced side-effects; however, the potential still exists.
Specific PDE4 isoforms are involved in the control of
specific cellular signaling pathways, through protein
phosphorylation or physical interaction with key compo-
nents. These interactions demonstrate unique functional
roles for a number of PDE4 isoforms. It must be pre-
sumed that there are many more of these interactions
remaining to be identified. It also provides a reason for
the potential expression of many PDE4 isoforms within a
single cell, all of which have one enzymatic function, that
of degrading cAMP. By selective expression of members
of the PDE4 family, cells are able to tightly control cAMP
regulation of their cellular signaling pathways.
Targeted disruption of these interactions and phos-
phorylation events provides a means of blocking inflam-
matory pathways while allowing PDE4 isoforms to
function as normal in other pathways. This strategy would
allow the development of novel anti-inflammatory agents
lacking any side-effects.
Crystallization of full-length PDE4 has so far proved
impossible due to the great flexibility of the N-terminal
controlling region. Thus, although the shape of the cata-
lytic domain is known and available for the development
of more specific inhibitors, only small regions of the
N-terminus in isolation have been modeled. Compounds
targeting the enzymes regulation within the N-terminal
controlling regions will require this information to lead to
enhanced binding potency.
The future of PDE4 inhibitors seems bright, with the
arrival of a new generation of potent, low side-effect
drugs on the market. The next goal will be the targeting of
selected PDE4 enzymes in order to block specific cellular
processes. Potentially, targeting the non-catalytic control-
ling regions of the enzyme would allow this.
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